Qi Jiazheng, Zhang Lingjing, Meng Fanhua, Yang Xiaoyu, Chen Baoxuan, Gao Lingqi, Zhao Xu, Luo Mengqiang
Fudan University, Huashan Hospital, Department of Anesthesiology, Shanghai, China.
Sun Yat-sen University, The First Affiliated Hospital, Department of Anesthesiology, Guangzhou, China.
Braz J Anesthesiol. 2025 Mar-Apr;75(2):844578. doi: 10.1016/j.bjane.2024.844578. Epub 2024 Nov 26.
The ideal anesthetic agents for sedation, considering their respiratory and cardiovascular benefits and other perioperative or postoperative outcomes, are still unclear. This systematic review and meta-analysis aimed to evaluate whether ciprofol has advantages over propofol for sedation, particularly concerning respiratory and cardiovascular outcomes and other relevant perioperative measures.
We conducted a comprehensive search of PubMed, Web of Science, the Cochrane Central Register of Controlled Trials, and two Chinese databases for randomized controlled trials comparing intravenous ciprofol and propofol for sedation. The primary outcome was the incidence of adverse respiratory events. Secondary outcomes included incidences of injection pain, hypotension, hypertension, bradycardia during surgery, perioperative nausea and vomiting, and postoperative awakening time. A random-effects model was used for more than four studies; otherwise, we employed the random-effects model with the Hartung-Knapp-Sidik-Jonkman adjustment.
Intravenous ciprofol resulted in fewer adverse respiratory events than propofol (Risk Ratio [RR = 0.44]; 95% Confidence Interval [95% CI 0.35-0.55], p < 0.001, I = 45%, low quality). It also showed a lower incidence of injection pain (RR = 0.12; 95% CI 0.08‒0.17, p < 0.001, I = 36%, low quality), intraoperative hypotension (RR = 0.64; 95% CI 0.52-0.77, p < 0.001, I = 58%, low quality), and nausea and vomiting than propofol (RR = 0.67; 95% CI 0.49-0.92; p = 0.01, I = 0%, moderate quality). However, no significant differences were observed for hypertension, bradycardia, and awakening time.
Ciprofol may be more effective than propofol in minimizing perioperative respiratory adverse events and maintaining hemodynamic stability during sedation without prolonging recovery time.
考虑到其对呼吸和心血管系统的益处以及其他围手术期或术后结局,用于镇静的理想麻醉药物仍不明确。本系统评价和荟萃分析旨在评估环泊酚在镇静方面是否优于丙泊酚,特别是在呼吸和心血管结局以及其他相关围手术期指标方面。
我们全面检索了PubMed、Web of Science、Cochrane对照试验中心注册库以及两个中文数据库,以查找比较静脉注射环泊酚和丙泊酚进行镇静的随机对照试验。主要结局是不良呼吸事件的发生率。次要结局包括注射痛、低血压、高血压、手术期间心动过缓、围手术期恶心和呕吐以及术后苏醒时间的发生率。对于四项以上的研究使用随机效应模型;否则,我们采用经Hartung-Knapp-Sidik-Jonkman调整的随机效应模型。
静脉注射环泊酚导致的不良呼吸事件少于丙泊酚(风险比[RR = 0.44];95%置信区间[95%CI 0.35 - 0.55],p < 0.001,I² = 45%,低质量)。它还显示出比丙泊酚更低的注射痛发生率(RR = 0.12;95%CI 0.08 - 0.17,p < 0.001,I² = 36%,低质量)、术中低血压发生率(RR = 0.64;95%CI 0.52 - 0.77,p < 0.001,I² = 58%,低质量)以及恶心和呕吐发生率(RR = 0.67;95%CI 0.49 - 0.92;p = 0.01,I² = 0%,中等质量)。然而,在高血压、心动过缓和苏醒时间方面未观察到显著差异。
在最小化围手术期呼吸不良事件以及在镇静期间维持血流动力学稳定性且不延长恢复时间方面,环泊酚可能比丙泊酚更有效。